Keiley Elizabeth M

General Counsel at Entasis Therapeutics Holdings Inc.; SVP & General Counsel at Oxford Immunotec Global PLC

Sold, on record
$191k
Dollars the filings state
Form 4 sales
4
Latest Oct 19, 2021
Form 144 notices
0
Proposed sales
Quarters with a sale
0 of the last 8
No sale in two years
Companies
2
Filed as an executive or holder

Companies

Sales by reason

0
Routine
4
Plan not stated
0
No plan
0
Unusual
Stacked: routine sales under a plan, sales whose filing does not state a plan, sales with no plan, and unusual sales.

Form 4 sales per year, every sale on record.

Sales chart range

Sales by company

Shares sold, every Form 4 sale on record.

Timeline

  1. Oct 19, 2021Plan not stated

    Entasis Therapeutics Holdings Inc.

    Sold 7.5% of their holdings

    $12k3,759 shares at $3.19

    Filed Oct 20, 2021Form 4

  2. Mar 4, 2019Plan not stated

    Oxford Immunotec Global PLC

    Sold 13.2% of their holdings

    $70k4,100 shares at $17.00

    Filed Mar 6, 2019Form 4

  3. Jun 15, 2017Plan not stated

    Oxford Immunotec Global PLC

    Sold 13.9% of their holdings

    $61k4,085 shares at $15.01

    Filed Jun 16, 2017Form 4

  4. Mar 20, 2017Plan not stated

    Oxford Immunotec Global PLC

    Sold 11.8% of their holdings

    $48k3,000 shares at $16.05

    Filed Mar 22, 2017Form 4

4 of 4

Every transaction

Every transaction on a Form 4 or Form 5 by Keiley Elizabeth M
TradedFiledStockRoleWhatAmountPriceValueHeld afterSource
Jul 11, 2022Jul 11, 2022Entasis Therapeutics Holdings Inc.General CounselOtherStock Option (right to buy)70,8330SEC
Jul 11, 2022Jul 11, 2022Entasis Therapeutics Holdings Inc.General CounselReturned to the company150,0000SEC
Jul 7, 2022Jul 11, 2022Entasis Therapeutics Holdings Inc.General CounselTendered17,572$2.20$39k0SEC
Jan 18, 2022Jan 19, 2022Entasis Therapeutics Holdings Inc.General CounselAwarded125,000167,572SEC
Nov 2, 2021Nov 3, 2021Entasis Therapeutics Holdings Inc.General CounselWithheld for tax3,669$2.94$11k42,572SEC
Oct 19, 2021Oct 20, 2021Entasis Therapeutics Holdings Inc.General CounselSold3,759$3.19$12k46,241SEC
Oct 19, 2021Oct 20, 2021Entasis Therapeutics Holdings Inc.General CounselAwarded25,00050,000SEC
Jul 16, 2021Feb 15, 2022Entasis Therapeutics Holdings Inc.General CounselReturned to the companyEmployee Stock Option (Right to Buy)25,0000SEC
Jul 16, 2021Feb 15, 2022Entasis Therapeutics Holdings Inc.General CounselAwardedEmployee Stock Option (Right to Buy)20,83320,833SEC
Jan 15, 2021Jan 19, 2021Entasis Therapeutics Holdings Inc.General CounselAwarded25,00025,000SEC
Jan 23, 2020Jan 27, 2020Entasis Therapeutics Holdings Inc.General CounselAwardedStock Option (Right to Buy)50,00050,000SEC
Mar 4, 2019Mar 6, 2019Oxford Immunotec Global PLCSVP & General CounselSold4,100$17.00$70k26,928SEC
Jan 1, 2019Jan 3, 2019Oxford Immunotec Global PLCSVP & General CounselWithheld for tax1,605$12.78$21k31,028SEC
Jun 13, 2018Jun 14, 2018Oxford Immunotec Global PLCSVP & General CounselWithheld for tax2,500$14.41$36k32,633SEC
Mar 15, 2018Mar 19, 2018Oxford Immunotec Global PLCSenior VP & General CounselAwardedShare Option (Right to Buy)47,58747,587SEC
Mar 15, 2018Mar 19, 2018Oxford Immunotec Global PLCSenior VP & General CounselAwarded10,88235,133SEC
Jan 1, 2018Jan 3, 2018Oxford Immunotec Global PLCSenior VP & General CounselWithheld for tax1,142$13.97$16k24,251SEC
Jun 15, 2017Jun 16, 2017Oxford Immunotec Global PLCSenior VP & General CounselSold4,085$15.01$61k25,393SEC
Jun 9, 2017Jun 13, 2017Oxford Immunotec Global PLCSenior VP & General CounselWithheld for tax1,136$14.63$17k29,478SEC
Mar 20, 2017Mar 22, 2017Oxford Immunotec Global PLCSenior VP & General CounselSold3,000$16.05$48k22,429SEC
Mar 20, 2017Mar 22, 2017Oxford Immunotec Global PLCSenior VP & General CounselExercised or settledShare Option (Right to Buy)11,1850SEC
Mar 20, 2017Mar 22, 2017Oxford Immunotec Global PLCSenior VP & General CounselExercised options11,185$0.81$9k30,614SEC
Feb 24, 2017Mar 6, 2017Oxford Immunotec Global PLCVP & General CounselAwardedShare Option (Right to Buy)26,66126,661SEC
Feb 24, 2017Mar 6, 2017Oxford Immunotec Global PLCVP & General CounselAwarded5,87022,429SEC
Mar 4, 2016Mar 8, 2016Oxford Immunotec Global PLCVP & General CounselAwardedShare Option (Right to Buy)31,49531,495SEC
Mar 4, 2016Mar 8, 2016Oxford Immunotec Global PLCVP & General CounselAwarded7,55916,559SEC
Jun 9, 2015Jun 11, 2015Oxford Immunotec Global PLCVP & General CounselAwarded9,0009,000SEC
Jan 16, 2015Jan 21, 2015Oxford Immunotec Global PLCVP & General CounselAwardedShare Option (Right to Buy)9,0009,000SEC

Sales and notices (4)

Form 144 notices and Form 4 sales by Keiley Elizabeth M
Source
Oct 19, 2021Oct 20, 2021Entasis Therapeutics Holdings Inc.General CounselForm 4 sale3,759$12k7.5%Plan not statedSEC
Mar 4, 2019Mar 6, 2019Oxford Immunotec Global PLCSVP & General CounselForm 4 sale4,100$70k13.2%Plan not statedSEC
Jun 15, 2017Jun 16, 2017Oxford Immunotec Global PLCSenior VP & General CounselForm 4 sale4,085$61k13.9%Plan not statedSEC
Mar 20, 2017Mar 22, 2017Oxford Immunotec Global PLCSenior VP & General CounselForm 4 sale3,000$48k11.8%Plan not statedSEC